MMP14 predicts a poor prognosis in patients with colorectal cancer

Matrix metalloproteinases (MMPs) are involved in most biological processes. Recently, MMP14 was reported to be up-regulated in some types of cancer and to promote cancer cell invasion and metastasis. However, there are few reports on the clinical significance of MMP14 in colorectal cancer (CRC). In this study, MMP14 expression was first investigated in The Cancer Genome Atlas (TCGA) and whole-genome expression microarray (GEO; Accession Number GSE39582) and then validated with our database. Univariate and multivariate analyses were performed to assess the association between prognostic factors and survival outcomes. MMP14 was upregulated at both the transcriptional and protein levels in cancer compared with normal tissues (P < .05), and high MMP14 expression was associated with advanced tumor stage in the 3 study cohorts. In the univariate Cox proportional hazard ratio analysis, MMP14 correlated significantly with prognosis in both the TCGA and GSE39582 databases (P < .05).In the validation cohort, patients with high MMP14 expression had lower 5-year disease-free survival (DFS; hazard ratio [HR] 6.707; 95% confidence interval [CI] 3.184, 14.128; P < .001) and overall survival (OS; HR 10.669; 95% CI 3.828, 29.737; P < .001) than those with low MMP14 expression. Multivariate survival analysis showed that MMP14 was an independent prognostic marker for both DFS (HR 5.776; 95% CI 2.719, 12.270; P < .001) and OS (HR 8.971; 95% CI 3.199, 25.156; P < .001). Clearly, MMP14 plays an important role in CRC progression and prognosis and could be a useful biomarker for prediction of survival after colectomy. (C) 2018 Elsevier Inc. All rights reserved.